Incretin Atlas › Trials › Phase III TG103 + metformin vs dulaglutide (EASD 2026)
Phase III TG103 + metformin vs dulaglutide (EASD 2026)
TG103 · t2d
Design
- Molecule(s)
- TG103
- Population
- t2d
- Phase
- 3
- Participants
- 211
- Duration
- 52 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 mg QW vs dulaglutide 1.5 mg QW (active comparator): HbA1c -1.25 | t2d china | 52 | 211 | — | — | −1.3 | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (1)
- 15 mg QW · hba1c · HKEX filing
Injection 15 mg group was higher than that in the dulaglutide 1.5 mg group (1.31% vs 1.25%),
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: Phase III TG103 + metformin vs dulaglutide (EASD 2026). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-iii-tg103-metformin-vs-dulaglutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.